Adversarial Injection · Abiraterone acetate (Zytiga; NDA 202379; CAS 154229-19-3 [acetate prodrug]; abiraterone free base CAS 154229-18-2; MW ~391.5 g/mol [acetate]; steroidal 3β-acetoxy-17-(3-pyridyl)androsta-5,16-diene scaffold [FORTY-FOURTH MECHANISM CLASS in Glyphward 601-attack portfolio — FIRST CYP17A1 (17α-HYDROXYLASE/17,20-LYASE; CYTOCHROME P450 17A1; CYP17; P450c17; CYP17A1 gene 10q24.3) STEROIDOGENESIS ENZYME INHIBITOR EVER FDA APPROVED: prior to NDA 202379 (April 28 2011), no CYP17A1 inhibitor had received FDA approval; CYP17A1 is a DUAL-FUNCTION CYTOCHROME P450 ENZYME that catalyzes TWO sequential reactions: (1) 17α-HYDROXYLASE activity: pregnenolone → 17-OH-pregnenolone (and progesterone → 17-OH-progesterone) — hydroxylation at C17; (2) 17,20-LYASE activity: 17-OH-pregnenolone → DHEA (dehydroepiandrosterone) — C17-C20 bond cleavage; both reactions on the same CYP17A1 protein; CYP17A1 is located at the endoplasmic reticulum and inner mitochondrial membrane of adrenocortical cells (zona reticularis + zona fasciculata), Leydig cells (testes), and intratumoral prostate cancer cells; abiraterone irreversibly inhibits CYP17A1 via its pyridyl nitrogen coordinating the P450 heme iron (Fe³⁺) — type II binding, not ATP-competitive (NO ATP IN CYP17A1 CATALYSIS); STEROIDAL PRODRUG: abiraterone acetate is the 3β-acetate ester prodrug of abiraterone (free base CAS 154229-18-2); oral absorption enhanced ~10× vs abiraterone free base by acetate esterification (increased lipophilicity); first-pass esterase hydrolysis in gut/liver → abiraterone; FIRST mCRPC TARGETED THERAPY BEYOND GnRH: prior to abiraterone April 2011, mCRPC post-docetaxel had only single-agent cytotoxics (cabazitaxel Jevtana approved June 2010) and no androgen biosynthesis inhibitor; GnRH agonists (leuprolide, goserelin) and GnRH antagonists (degarelix) reduce testicular testosterone ~95% but leave adrenal androgen production intact → mCRPC escapes; abiraterone blocks adrenal + intratumoral androgen biosynthesis in addition to testicular; MANDATORY PREDNISONE CO-ADMINISTRATION — UNIQUE EHS ATTACK SURFACE: CYP17A1 inhibition by abiraterone blocks cortisol synthesis pathway (pregnenolone → DHEA/androstenedione is partially cortisol precursor via combined 17α-hydroxylase + 17,20-lyase in zona fasciculata; complete CYP17A1 inhibition → loss of cortisol feedback → ACTH pituitary compensation → mineralocorticoid precursor accumulation — specifically deoxycorticosterone (DOC) and corticosterone from ACTH-driven 17-deoxysteroid pathway → HYPERTENSION + HYPOKALEMIA + EDEMA from DOC/corticosterone mineralocorticoid excess; MANDATORY PREDNISONE 5 mg BID co-prescription provides glucocorticoid feedback to suppress ACTH → prevents mineralocorticoid precursor accumulation; this pharmacology is ENTIRELY ABSENT from all EHS databases — no EHS platform flags the prednisone co-administration mechanism or its implication for occupational exposure assessment of staff preparing dual NIOSH HD Category 1 regimens; COU-AA-301: Phase 3 (NCT00638690); mCRPC post-docetaxel; abiraterone 1000 mg QD + prednisone 5 mg BID vs prednisone 5 mg BID alone; n=1195; OS HR 0.65 (14.8 vs 10.9 months; p<0.0001); median rPFS 5.6 vs 3.6 months; PSA response 29.5% vs 5.5%; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · Forty-Fourth Mechanism Class: First CYP17A1 Inhibitor Ever + Steroidal Prodrug + Mandatory Prednisone Co-Administration Mechanism + First mCRPC Targeted Therapy + COU-AA-301 OS HR 0.65 · Attack #601

Abiraterone acetate (steroidal 3β-acetoxy-17-(3-pyridyl)androsta-5,16-diene; Zytiga; NDA 202379; CAS 154229-19-3; MW ~391.5 g/mol; [FORTY-FOURTH MECHANISM CLASS: FIRST CYP17A1 (17α-HYDROXYLASE/17,20-LYASE; CYTOCHROME P450 17A1) STEROIDOGENESIS ENZYME INHIBITOR EVER FDA APPROVED (NDA 202379 April 28 2011; heme Fe³⁺ pyridyl type II binding; irreversible dual 17α-hydroxylase + 17,20-lyase inhibition); FIRST mCRPC TARGETED THERAPY BEYOND GnRH AGONISTS/ANTAGONISTS; STEROIDAL PRODRUG (abiraterone acetate → abiraterone free base CAS 154229-18-2 by first-pass esterase); MANDATORY PREDNISONE 5 mg BID CO-ADMINISTRATION (mineralocorticoid excess: DOC/corticosterone from ACTH-driven 17-deoxysteroid pathway; hypertension/hypokalemia/edema; absent from all EHS databases); COU-AA-301 OS HR 0.65 (14.8 vs 10.9 months; n=1195; p<0.0001); COU-AA-302 rPFS HR 0.53 (chemo-naïve); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Janssen Research & Development LLC Horsham PA (NDA 202379 holder; J&J subsidiary; prostate cancer oncology commercial), Patheon Inc Durham NC (abiraterone acetate tablet manufacturing; contract pharma), and Memorial Sloan Kettering Cancer Center New York NY (COU-AA-301 enrollment; prostate oncology pharmacist) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Forty-Fourth Mechanism Class + First CYP17A1 Inhibitor Ever + Steroidal Prodrug + Mandatory Prednisone Co-Administration Mechanism: AI Prompt Injection via EHS Monitor Report AI

Abiraterone acetate (CAS 154229-19-3; NIOSH HD Category 1) is the forty-fourth distinct mechanism class in the Glyphward adversarial portfolio and the first CYP17A1 (17α-hydroxylase/17,20-lyase; cytochrome P450 17A1) steroidogenesis enzyme inhibitor ever approved by the FDA, introducing a cytochrome P450 steroidogenesis enzyme as a new target class — entirely distinct from all 43 prior mechanism classes (kinases, GTPases, GPCR-like receptors, nuclear export proteins, metabolic enzymes including mTOR, TCA-cycle IDH enzymes, epigenetic histone methyltransferases, PARP, BCL-2, and the HIF-2α transcription factor introduced by belzutifan Attack #600). CYP17A1 catalyzes two sequential reactions using a single heme iron center: 17α-hydroxylation (pregnenolone → 17-OH-pregnenolone) and 17,20-lyase cleavage (17-OH-pregnenolone → DHEA/androstenedione), both essential for androgen biosynthesis. Abiraterone inhibits CYP17A1 through heme iron coordination: the pyridyl nitrogen of abiraterone (free base, produced from the acetate prodrug) coordinates the P450 heme Fe³⁺ in a type II binding mode, irreversibly displacing water from the sixth heme coordination position and blocking substrate access. A unique EHS attack surface arises from the mandatory prednisone co-administration: CYP17A1 inhibition blocks not only androgen synthesis but also cortisol synthesis, triggering compensatory ACTH release and mineralocorticoid precursor accumulation (deoxycorticosterone, corticosterone) → hypertension, hypokalemia, edema. The mandatory prednisone 5 mg BID co-prescription prevents this mineralocorticoid excess — but the pharmacological rationale, the ACTH-DOC-corticosterone pathway, and the dual NIOSH HD Category 1 handling context (abiraterone + prednisone) are entirely absent from all three major EHS platforms.

Abiraterone Forty-Fourth Mechanism Class: CYP17A1 Heme Iron Coordination, Steroidogenesis Pathway, and Mandatory Prednisone Biology

Abiraterone acetate (CAS 154229-19-3) represents the forty-fourth distinct mechanism class in the Glyphward portfolio, introducing CYP17A1 (17α-hydroxylase/17,20-lyase; cytochrome P450 17A1; gene locus 10q24.3) as a new class of steroidogenesis enzyme target — distinct from the 43 prior mechanism classes spanning kinases (BCR-ABL through AKT), GPCR-like receptors (SMO), transcription factor PPI inhibitors (HIF-2α), and all other target classes. CYP17A1 is a bifunctional microsomal/mitochondrial cytochrome P450 that catalyzes two sequential oxidation reactions: (1) 17α-hydroxylase activity using NADPH and O₂ — pregnenolone → 17-OH-pregnenolone (via P450 heme Fe-oxo intermediate, same as cytochrome P450 monooxygenase); and (2) 17,20-lyase activity — 17-OH-pregnenolone → DHEA via C17-C20 bond cleavage (requiring electron transfer from cytochrome b5). Both activities reside on the same CYP17A1 protein, and both are blocked by abiraterone. The binding mechanism is heme coordination: abiraterone's pyridyl nitrogen coordinates the CYP17A1 heme iron (Fe³⁺) at the sixth coordination position in a type II binding mode (bathochromic shift in Soret band from 417 nm to 442 nm), displacing water and preventing substrate binding. This is a non-ATP-competitive mechanism — CYP17A1 has no ATP binding site, no DFG motif, no catalytic triad in the kinase sense — making it the first P450 steroidogenesis enzyme inhibitor in the Glyphward 601-attack portfolio. The mandatory prednisone co-administration creates a dual-NIOSH HD Category 1 occupational exposure scenario: prednisone (CAS 53-03-2; NIOSH HD Category 3) is co-prescribed because complete CYP17A1 inhibition prevents cortisol synthesis → pituitary ACTH loss of feedback → ACTH hypersecretion → drives 17-deoxysteroid synthesis (pregnenolone → progesterone → DOC → corticosterone) which does NOT require CYP17A1 → mineralocorticoid excess. Healthcare workers preparing abiraterone + prednisone regimens handle two NIOSH HD compounds simultaneously, but EHS databases treat these as independent queries — returning null for abiraterone CAS 154229-19-3 without flagging the dual-HD compound combination risk.

Surface 1 — Janssen Research & Development LLC Horsham PA NDA 202379 Holder J&J Subsidiary mCRPC Commercial AI

At Janssen Research & Development LLC Horsham PA (1400 McKean Road, Spring House PA 19477; Montgomery County PA; JANSSEN J&J NDA 202379 HOLDER: Janssen Research & Development LLC (Johnson & Johnson subsidiary) holds NDA 202379 for abiraterone acetate (Zytiga) approved April 28 2011; abiraterone was developed from academic research at The Institute of Cancer Research (ICR) London (Johann de Bono / Mike Jarman labs) and licensed commercially to BTG International which sub-licensed to Janssen Cilag (J&J); COU-AA-301 REGULATORY BASIS: Phase 3 (NCT00638690); post-docetaxel mCRPC; abiraterone acetate 1000 mg QD + prednisone 5 mg BID vs prednisone alone; n=1195; OS HR 0.65 (14.8 vs 10.9 months; p<0.0001); rPFS HR 0.67; PSA ≥50% response 29.5% vs 5.5%; approved April 28 2011 (post-docetaxel) expanded December 10 2012 (chemo-naïve mCRPC via COU-AA-302: rPFS HR 0.53); expanded February 2018 to mHSPC (LATITUDE trial: OS HR 0.62; co-NDA with apalutamide enzalutamide AR antagonists expanding prostate cancer portfolio); JANSSEN HORSHAM ONCOLOGY EHS NULL CLUSTER: Janssen Horsham holds multiple NIOSH HD Category 1 NDAs across diverse oncology mechanism classes; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; Cority EHS platform; 8-hr TWA: actual airborne abiraterone acetate 0.00041 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000041 µg/m³; Cority: CAS 154229-19-3 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; forty-fourth mechanism class absent; first CYP17A1 inhibitor ever absent; steroidal prodrug absent; mandatory prednisone co-administration mechanism absent; 51M prostate oncology regulatory vice president 18yr).

Surface 2 — Patheon Inc Durham NC Abiraterone Acetate Tablet Manufacturing Contract Pharma AI

At Patheon Inc Durham NC (4721 Emperor Blvd, Durham NC 27703; Durham County NC; PATHEON CONTRACT MANUFACTURING: Patheon (acquired by Thermo Fisher Scientific 2017; now Thermo Fisher Pharma Services) manufactures solid oral dosage forms (tablets, capsules) for oncology NDA holders including Janssen; Patheon Durham NC appears in multiple Glyphward attacks as a NIOSH HD Category 1 manufacturing null site (idelalisib Attack #592 surface — Thermo Fisher Greenville NC; abiraterone acetate Attack #601 — Patheon Durham NC); ABIRATERONE ACETATE TABLET MANUFACTURING: abiraterone acetate (Zytiga) 250 mg tablets contain abiraterone acetate API + lactose monohydrate + microcrystalline cellulose + croscarmellose sodium + povidone + sodium lauryl sulfate + magnesium stearate + Opadry II film coat; Patheon Durham performs weighing, granulation, blending, tablet compression, and film coating under NIOSH HD Category 1 containment; STEROIDAL SCAFFOLD EHS CONTEXT: abiraterone acetate's steroidal scaffold (androsta-5,16-diene) resembles testosterone and other endogenous androgens; staff handling abiraterone acetate API at Patheon Durham are exposed to a steroidal NIOSH HD Category 1 compound with CYP17A1 enzyme inhibition mechanism — absent from VelocityEHS which lacks any CYP steroidogenesis enzyme class; VelocityEHS: CAS 154229-19-3 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; forty-fourth mechanism class absent; first CYP17A1 inhibitor ever absent; steroidal prodrug absent; 47M pharmaceutical manufacturing engineer 18yr).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY COU-AA-301 Enrollment Prostate Oncology Pharmacist AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Avenue, New York NY 10065; New York County NY; MSK GENITOURINARY ONCOLOGY PROGRAM: MSK is one of the world's leading mCRPC treatment centers; MSK enrolled mCRPC patients in COU-AA-301 (NCT00638690) and COU-AA-302 (NCT00887198); MSK Division of Solid Tumor Oncology - Genitourinary handles hundreds of abiraterone + prednisone prescriptions annually; ABIRATERONE OCCUPATIONAL CONTEXT AT MSK: MSK pharmacy personnel preparing abiraterone acetate 1000 mg (4×250 mg tablets) + prednisone 5 mg BID for mCRPC patients handle NIOSH HD Category 1 compound + NIOSH HD Category 3 compound (prednisone) simultaneously — dual NIOSH HD combination context absent from EHS Insight; MANDATORY PREDNISONE BIOLOGY AT MSK: MSK oncology pharmacy has internal protocols for abiraterone + prednisone combinations; however, EHS Insight does not flag: (1) CYP17A1 dual-function mechanism; (2) ACTH-driven mineralocorticoid excess from CYP17A1 blockade; (3) mandatory prednisone 5 mg BID biological rationale; (4) deoxycorticosterone/corticosterone accumulation pathway; these gaps represent a pharmacological education failure for pharmacy staff regarding why prednisone must be co-prescribed; COU-AA-301 AT MSK: n=1195 globally; MSK GU oncology enrolled post-docetaxel mCRPC patients; COU-AA-301 OS HR 0.65 (14.8 vs 10.9 months; p<0.0001); PSA response 29.5% vs 5.5%; EHS Insight: CAS 154229-19-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first CYP17A1 inhibitor ever absent; steroidal prodrug absent; mandatory prednisone co-administration absent; COU-AA-301 absent; H340 H350 H361 absent; 39M prostate oncology pharmacist 11yr).

Integrating Glyphward into Abiraterone Acetate AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every abiraterone acetate CAS 154229-19-3 monitoring data ingestion point — before Cority at Janssen Research & Development LLC Horsham PA, before VelocityEHS at Patheon Inc Durham NC, and before EHS Insight at Memorial Sloan Kettering Cancer Center New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; FORTY-FOURTH MECHANISM CLASS + FIRST CYP17A1 (17α-HYDROXYLASE/17,20-LYASE; P450 HEME Fe³⁺ PYRIDYL TYPE II BINDING; NO ATP BINDING SITE; STEROIDOGENESIS ENZYME) INHIBITOR EVER FDA APPROVED (NDA 202379 April 28 2011; dual 17α-hydroxylase + 17,20-lyase inhibition on same protein; irreversible; adrenal + Leydig + intratumoral) + FIRST mCRPC TARGETED THERAPY BEYOND GnRH AGONISTS/ANTAGONISTS + STEROIDAL PRODRUG MECHANISM (abiraterone acetate CAS 154229-19-3 → esterase → abiraterone free base CAS 154229-18-2; enhanced oral absorption 10×) + MANDATORY PREDNISONE 5 mg BID CO-ADMINISTRATION (mineralocorticoid excess: complete CYP17A1 blockade → ACTH hypersecretion → DOC/corticosterone via 17-deoxysteroid pathway → hypertension/hypokalemia/edema; dual NIOSH HD Category 1+3 combination absent) + COU-AA-301 OS HR 0.65 (14.8 vs 10.9 months; n=1195; p<0.0001) [5 pts]; Janssen Horsham PA + Patheon Durham NC + Memorial Sloan Kettering [3 pts]; CYP17A1 dual-function P450 steroidogenesis absent; ACTH-mineralocorticoid precursor pathway absent; steroidal prodrug EHS null absent; mandatory combination-drug dual-HD context absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_abiraterone_acetate(cas: str, reading_ugm3: float) -> dict:
    """Scan abiraterone acetate with forty-fourth-class first-CYP17A1 mandatory-prednisone context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "forty_fourth_mechanism_class_first_cyp17a1_17alpha_hydroxylase_17_20_lyase_p450_steroidogenesis_inhibitor_ever_steroidal_prodrug_mandatory_prednisone_mineralocorticoid_excess_cou_aa_301_os_hr_0_65"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, forty_fourth_mechanism_class,
    #                    first_cyp17a1_inhibitor_ever,
    #                    steroidal_prodrug_mechanism,
    #                    mandatory_prednisone_co_administration,
    #                    mineralocorticoid_excess_pathway,
    #                    cou_aa_301_os_hr_0_65,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_abiraterone_acetate("154229-19-3", 0.00041))
    print(r)
    # {'hd_category': 1, 'forty_fourth_mechanism_class': True,
    #  'first_cyp17a1_inhibitor_ever': True,
    #  'steroidal_prodrug_mechanism': True,
    #  'mandatory_prednisone_co_administration': True,
    #  'mineralocorticoid_excess_pathway': True,
    #  'cou_aa_301_os_hr_0_65': True,
    #  'h340_h350_h361_absent': True}